The following is a summary of “Structural equation modeling for identifying the drivers of health-related quality of life improvement experienced by patients with migraine receiving eptinezumab,” published in the March 2024 issue of Pain by Jönsson et al.
Researchers concluded a retrospective study exploring how eptinezumab treatment impacts HRQoL by evaluating the mediating effects of reduced monthly migraine days and improved patient-identified most bothersome symptoms (PI-MBS).
They utilized data from the DELIVER study, which involved patients with 2–4 prior unsuccessful migraine preventive treatments, in two structural equation models analyzing factors contributing to improvements in HRQoL through Migraine-Specific Quality-of-Life Questionnaire (MSQ) scores. A single hidden variable explained HRQoL in DELIVER. One model considered all migraine symptoms, while another focused solely on PI-MBS. Intermediate variables included MMDs, other symptoms, and PI-MBS.
The results showed that in the first model, decreases in MMDs and other canonical symptoms contributed to 35% (standardized effect size [SES] − 0.11) and 25% (SES − 0.08) of HRQoL enhancement, respectively, with 41% (SES −0.13) of improvement attributed to “direct treatment effect,” unexplained by mediators. In the second model, eptinezumab led to significant HRQoL enhancement (86%; SES −0.26), primarily due to MMD reduction (17%; SES −0.05) and change in PI-MBS (69%; SES −0.21).
Investigators concluded that improvements in HRQoL seen with eptinezumab were mainly due to its impact on migraine frequency and patients’ most bothersome symptoms.
Source: thejournalofheadacheandpain.biomedcentral.com/articles/10.1186/s10194-024-01752-z
